The Next-Generation GLP-1 Pipeline: Novo Nordisk, Lilly, Amgen, Boehringer, Viking, and the 2027-2028 Landscape
The GLP-1 pipeline of 2026-2028 will reshape the obesity and diabetes treatment landscape. Multi-agonist compounds (GLP-1/GIP/glucagon triples), oral small-molecule agonists that could dramatically change access, and new mechanisms targeting fat-specific weight loss are all approaching approval or Phase 3 completion. Here's the pipeline landscape as of mid-2026, what's approaching approval, what mechanisms are being tested, and how the market is likely to evolve.
The 60-second version
The GLP-1 pipeline for 2026-2028 includes multiple potentially transformative compounds. Novo Nordisk's CagriSema (semaglutide + cagrilintide) approaches full launch after 2026 approvals; the company's oral semaglutide 25 mg for obesity is under review. Lilly's retatrutide (GLP-1/GIP/glucagon triple agonist) reported extraordinary Phase 3 weight loss results and approaches likely 2027 approval. Lilly's orforglipron oral small-molecule GLP-1 achieved FDA approval in 2026 and could dramatically expand access due to manufacturability advantages. Amgen's MariTide (GLP-1/GIP with antibody-conjugate design) is in Phase 3 with monthly dosing. Boehringer/Zealand's survodutide reported 19-20% Phase 3 weight loss. Viking Therapeutics' VK2735 in dual oral and injectable forms is in Phase 3. Also in development: myostatin-inhibitor combinations for fat-selective loss, novel activin/GDF-family compounds, and multiple insulin-sensitizing additions. This pipeline overview covers each major program's status, mechanism, and likely market impact.
Key takeaways
- The 2026-2028 GLP-1 pipeline will end the semaglutide/tirzepatide duopoly with multiple compounds entering the market.
- Novo Nordisk's CagriSema (semaglutide + cagrilintide) approaches full launch with ~22.7% weight loss at 68 weeks.
- Lilly's retatrutide TRIUMPH-1 (topline May 21, 2026) reported up to 30.3% weight loss at 68 weeks, the deepest ever for obesity pharmacotherapy; approval likely 2027.
- Lilly's orforglipron oral small-molecule GLP-1 approved in 2026 could dramatically expand access through better manufacturing economics.
- Amgen's MariTide is a GLP-1/GIP antibody-conjugate with monthly dosing, in Phase 3.
- Boehringer/Zealand's survodutide (GLP-1/glucagon) shows strong hepatic effects positioning for MASH indication.
- Viking Therapeutics' VK2735 in dual oral and injectable forms is in Phase 3.
- Muscle-preserving combinations (bimagrumab, SARM+GLP-1, follistatin approaches) address the muscle loss concern with current therapy.
- The retatrutide Phase 3 readouts and cardiovascular outcomes data will define the 2027 landscape.
- Research peptide access to pipeline compounds typically follows Phase 2 publication; quality and COA verification are increasingly important.
Why 2026-2028 will reshape the landscape
The current market is dominated by two active pharmaceutical ingredients, semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). Between 2026 and 2028, that duopoly will fragment. Multiple compounds with either superior efficacy, better dosing convenience, better tolerability, better manufacturability, or novel mechanisms will enter the market.
The changes fall into several distinct categories: multi-agonist injectable compounds pushing efficacy beyond current tirzepatide levels, oral GLP-1 alternatives that may dramatically expand access, monthly-dosed antibody-conjugate compounds, and mechanistically-different compounds addressing fat-selective loss (as opposed to muscle loss that concerns current GLP-1 users). Each category has multiple candidates.
Novo Nordisk's pipeline
CagriSema (semaglutide + cagrilintide), approaching launch
Mechanism: Fixed-dose combination of semaglutide (GLP-1 receptor agonist) and cagrilintide (long-acting amylin analog). Amylin adds distinct appetite-suppression and gastric-emptying mechanisms to the GLP-1 backbone.
Phase 3 evidence: REDEFINE 1 (published December 2024) reported ~22.7% weight loss at 68 weeks vs semaglutide alone at ~16.1%. Additional REDEFINE trials in T2D and specific populations reported in 2025-2026.
Regulatory status (mid-2026): Submitted for approval; European launch likely late 2026 with US approval progressing.
Market impact: Positions Novo Nordisk to compete with tirzepatide efficacy while leveraging established semaglutide safety profile.
Amycretin, earlier pipeline
Mechanism: Combined GLP-1 and amylin receptor agonist in a single molecule.
Status: Phase 2 data reported in 2025 was highly promising with weight loss effects potentially exceeding current agents. Phase 3 initiated in 2025-2026 with likely 2028+ approval timeline.
Oral semaglutide 25 mg for obesity
Status: Higher-dose oral semaglutide formulation for obesity indication. Under review with potential approval late 2026 to early 2027.
Market impact: Expands oral GLP-1 options for obesity indication.
Eli Lilly's pipeline
Retatrutide, approaching 2027 approval
Mechanism: Triple agonist targeting GLP-1, GIP, and glucagon receptors. The glucagon addition potentially adds distinct metabolic effects including increased energy expenditure that may explain the extraordinary Phase 2 results.
Phase 2 evidence (published 2023): 24.2% weight loss at 48 weeks, the largest weight loss ever reported for a pharmacological obesity intervention at that timepoint. Suggested a ceiling above 25% at longer durations.
Phase 3 program: TRIUMPH trials in obesity, diabetes, obstructive sleep apnea, and cardiovascular outcomes. Multiple 2026 readouts.
Regulatory status (mid-2026): Phase 3 completing; anticipated FDA submission 2026-2027 with potential 2027 approval.
Market impact: Would establish new efficacy benchmark exceeding current tirzepatide levels. Cardiovascular outcomes data will be critical for adoption.
Orforglipron, approved 2026
Mechanism: Oral small-molecule GLP-1 receptor agonist. Unlike semaglutide (peptide requiring SNAC absorption enhancer), orforglipron is a small molecule with straightforward oral bioavailability.
Phase 3 evidence: ACHIEVE-1 and ACHIEVE-3 reported strong efficacy for both T2D and obesity indications. Weight loss substantially better than current oral semaglutide 14 mg dose.
Regulatory status: FDA approved in 2026 for T2D and obesity.
Market impact: Potentially transformative for access. Small-molecule oral GLP-1 has dramatically different manufacturing economics than injectable peptides, could substantially expand the addressable market.
Tirzepatide expansion indications
Existing approvals: T2D (Mounjaro), obesity (Zepbound), obstructive sleep apnea (Zepbound).
Pipeline expansions: Heart failure with preserved ejection fraction (HFpEF), MASH (metabolic dysfunction-associated steatohepatitis), broader cardiovascular outcomes.
Regulatory status: SURMOUNT-CVOT data expected 2026-2027.
Amgen's MariTide (maridebart cafraglutide), Phase 3
Mechanism: Antibody-conjugate design combining GLP-1 receptor agonism with GIP receptor antagonism (the opposite of tirzepatide's dual agonism). Long half-life enables monthly dosing.
Phase 2 evidence (published early 2025): Approximately 16-20% weight loss at 52 weeks with monthly dosing. Different tolerability profile than daily/weekly compounds.
Phase 3 program: MARITIME and related trials in obesity and T2D. Multiple readouts 2026-2027.
Regulatory status: Phase 3 ongoing. Potential 2027-2028 approval.
Market impact: Monthly dosing versus weekly could reduce compliance burden. Different mechanism could suit patients who don't tolerate GLP-1/GIP dual agonism.
Boehringer Ingelheim / Zealand's survodutide, Phase 3
Mechanism: Dual GLP-1/glucagon receptor agonist. Glucagon effects target hepatic fat and energy expenditure.
Phase 2 evidence: Substantial weight loss (~19% at 46 weeks in obesity trials) with distinct hepatic benefits.
Phase 3 program: SYNCHRONIZE trials in obesity, T2D, and MASH (metabolic dysfunction-associated steatohepatitis).
Regulatory status: Phase 3 ongoing with 2027-2028 potential approvals.
Market impact: Strong hepatic effects position for MASH indication where current GLP-1s show more modest liver-specific outcomes.
Viking Therapeutics' VK2735, Phase 3
Mechanism: Dual GLP-1/GIP receptor agonist. Similar mechanism to tirzepatide.
Formulations: Both injectable (weekly) and oral formulations in development.
Phase 2 evidence: ~14.7% weight loss at 13 weeks (injectable), with Phase 2 data suggesting potential for stronger effects at longer durations. Oral formulation Phase 2 data was similarly promising.
Regulatory status: Phase 3 initiated 2025-2026. Approval likely 2028 or later given trial timelines.
Market impact: If Phase 3 confirms Phase 2 results, adds a fourth major dual agonist to the market. Oral formulation adds access flexibility.
Roche's CT-388, Phase 2/3
Mechanism: Dual GLP-1/GIP receptor agonist acquired through the Carmot Therapeutics acquisition.
Phase 1 evidence: 18.8% weight loss at 24 weeks (a very strong signal from Phase 1 duration).
Status: Phase 2 completing with Phase 3 pending.
Structure Therapeutics, oral GLP-1
Compound: GSBR-1290 (aleniglipron), oral small-molecule GLP-1 receptor agonist.
Status: Phase 2b/3 in obesity and T2D.
Market impact: Another oral small-molecule competitor to orforglipron, with slightly different pharmacology.
Muscle preservation and body composition frontier
A major frontier in 2026 involves combining GLP-1 compounds with muscle-preserving mechanisms to address the muscle loss concern in current therapy.
Bimagrumab (activin receptor antibody)
Mechanism: Monoclonal antibody blocking activin type II receptors, resulting in muscle mass increase and fat mass reduction.
Phase 2 evidence: BELIEVE trial data reported substantial fat mass reduction with muscle preservation when combined with semaglutide vs semaglutide alone.
Status: Phase 3 planning.
Market impact: If effective, could address the muscle loss concern that limits current GLP-1 use.
Enobosarm (SARM) + GLP-1 combinations
Mechanism: Selective androgen receptor modulator combined with GLP-1 for muscle preservation during weight loss.
Status: Trials in progress.
Follistatin gene therapy approaches
See our Follistatin peptide page for the emerging myostatin-inhibition landscape.
The broader market implications
Access expansion
Oral small-molecule compounds (orforglipron, GSBR-1290) could substantially reduce manufacturing costs versus injectable peptides. This may translate to dramatically expanded access, potentially bringing prices to levels where broader payer coverage and patient access become feasible.
Efficacy ceiling elevation
If retatrutide Phase 3 confirms Phase 2 efficacy (~24%+ weight loss at 48 weeks), it establishes a new efficacy standard. Users who don't achieve target results on semaglutide or tirzepatide will have additional options.
Convenience improvements
Monthly dosing (MariTide) versus weekly could reduce injection burden for patients. Oral options eliminate injection burden entirely for those who tolerate the strict Rybelsus-style administration requirements.
Indication expansion
Multiple compounds are being studied for HFpEF, MASH, chronic kidney disease, sleep apnea, and broader cardiometabolic outcomes. GLP-1 therapy is increasingly recognized as broader cardiometabolic intervention rather than narrow diabetes/obesity treatment.
Tolerability differentiation
The distinct mechanisms across compounds (dual GLP-1/GIP, triple GLP-1/GIP/glucagon, GLP-1/glucagon, GLP-1 with GIP antagonism, amylin-combined) will likely produce distinct tolerability profiles. Patients who don't tolerate one class may tolerate another.
Community and research peptide implications
The Phase 2/3 pipeline creates a specific pattern: research peptide vendors typically obtain synthesis routes for high-profile compounds shortly after Phase 2 publication. Retatrutide research peptide availability preceded its clinical approval; similar patterns will likely occur for CagriSema components, survodutide, and other pipeline compounds.
The community-relevant considerations:
- Research peptide "retatrutide" often has quality and identity issues; verify COAs carefully. See our COA article.
- Complex compounds like retatrutide are harder to synthesize accurately than simpler compounds. Purity variability is likely higher.
- The March 2026 DOJ enforcement affected multiple research peptide vendors; the compliance landscape continues evolving. See our State of the Peptide Market 2026.
- Compounded GLP-1 access is separately affected by the 2024-2025 shortage resolution status; see our compounded GLP-1 in 2026 article.
Timeline summary
- 2026: CagriSema likely launch; oral semaglutide 25 mg possible approval; orforglipron approved
- 2027: Retatrutide anticipated approval; MariTide potentially approved; SURMOUNT-CVOT cardiovascular data
- 2028: Survodutide likely approval; VK2735 potentially approved; multiple oral competitors in market
- 2028+: Amycretin, next-generation combinations, muscle-preserving combinations mature into market
Frequently asked questions
When will retatrutide be approved?
Phase 3 TRIUMPH program is completing in 2026 with anticipated FDA submission 2026-2027 and potential 2027 approval. Cardiovascular outcomes data will be critical for adoption. See our retatrutide page.
Is orforglipron better than semaglutide?
Orforglipron is an oral small-molecule GLP-1 with different pharmacology than peptide GLP-1s. Phase 3 efficacy was strong for T2D and obesity. The primary advantage is dramatically better manufacturing economics that could improve access. Head-to-head efficacy against injectable semaglutide favors the injectable at higher doses; the access implications may matter more.
What's CagriSema and how does it compare to Wegovy?
CagriSema is Novo Nordisk's fixed-dose combination of semaglutide (Wegovy's active ingredient) and cagrilintide (a long-acting amylin analog). REDEFINE 1 reported ~22.7% weight loss vs ~16.1% for semaglutide alone. It essentially adds amylin biology to the semaglutide backbone.
Will MariTide really only need monthly injections?
Yes, the antibody-conjugate design gives MariTide a long half-life supporting monthly dosing. Phase 2 confirmed this dosing schedule. Whether tolerability at monthly intervals is as good as weekly dosing of other compounds is a key Phase 3 question.
Which pipeline compound will have the highest weight loss?
Retatrutide. TRIUMPH-1 topline (May 21, 2026) reported up to 30.3% average weight loss at 68 weeks, the deepest weight-loss result reported for any pharmacological obesity intervention. TRIUMPH-4 (Dec 2025, obesity + knee OA) reported 28.7% at 68 weeks. Both readouts confirm and exceed the Phase 2 signal (24.2% at 48 weeks) at Phase 3 scale.
What about survodutide?
Boehringer/Zealand's GLP-1/glucagon dual agonist. Phase 2 showed ~19% weight loss. The glucagon mechanism adds hepatic benefits positioning survodutide for MASH indication where current GLP-1s show more modest liver-specific outcomes. Phase 3 SYNCHRONIZE trials ongoing.
Will pipeline compounds be affordable?
Oral small-molecule compounds (orforglipron, GSBR-1290) have substantially better manufacturing economics than injectable peptides. This could lead to lower prices and broader access. Injectable pipeline compounds face similar cost pressures as current agents but with more competition potentially reducing prices.
What's the deal with muscle preservation combinations?
Current GLP-1 users lose muscle along with fat (typically 25-40% of weight loss). Bimagrumab (activin receptor antibody) and SARM-based combinations aim to selectively preserve muscle during weight loss. Phase 2 evidence for bimagrumab + semaglutide is encouraging; Phase 3 trials are the next step.
Should I try to get research peptide retatrutide?
Research peptide retatrutide is complex to synthesize with meaningful quality variability. See our COA article for verification framework. The March 2026 DOJ enforcement actions affected multiple research peptide vendors. Waiting for FDA approval provides substantially better safety and quality assurance.
Will retatrutide replace tirzepatide?
Complicated question. If retatrutide's Phase 3 efficacy matches Phase 2, it may become the preferred choice for maximum efficacy. However, tirzepatide has extensive real-world experience, established safety profile, and multiple approved indications. Both are likely to coexist with retatrutide taking the higher-efficacy end of the market and tirzepatide continuing for many patient contexts.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
- Novo Nordisk. REDEFINE 1 phase 3 results for CagriSema. Company announcement December 2024. https://www.novonordisk.com/news-and-media/latest-news.html
- Wharton S, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888. https://pubmed.ncbi.nlm.nih.gov/37351564/
- Amgen. MariTide (maridebart cafraglutide) Phase 2 obesity results. 2025. https://www.amgen.com/newsroom/press-releases
- Le Roux CW, et al. Survodutide phase 2 obesity results. Lancet Diabetes Endocrinol. 2024. https://pubmed.ncbi.nlm.nih.gov/?term=survodutide+phase+2
- Heymsfield SB, et al. BELIEVE trial: Bimagrumab + semaglutide for body composition changes in obesity. 2024. https://pubmed.ncbi.nlm.nih.gov/?term=bimagrumab+semaglutide
We update articles as new trials publish and the evidence base evolves. Last reviewed: July 2026.